Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Prothena ( (PRTA) ) has provided an update.
On June 18, 2025, Prothena Corporation plc announced a significant reduction in its workforce by approximately 63% to cut operating costs and focus on its remaining wholly-owned programs and business development activities. This decision follows the company’s earlier announcement on May 23, 2025, to discontinue the development of birtamimab. The workforce reduction is expected to be completed by the end of the fourth quarter of 2025, with affected employees receiving severance packages. The company anticipates recognizing $16 to $20 million in severance and related benefits expenses. Additionally, the employment of Chief Regulatory Officer Carol D. Karp and Chief People Officer David A. Ford will terminate on August 1, 2025, as part of this reduction, triggering severance benefits and stock option adjustments.
The most recent analyst rating on (PRTA) stock is a Buy with a $84.00 price target. To see the full list of analyst forecasts on Prothena stock, see the PRTA Stock Forecast page.
Spark’s Take on PRTA Stock
According to Spark, TipRanks’ AI Analyst, PRTA is a Neutral.
Prothena’s overall stock score is primarily influenced by its financial performance, characterized by ongoing losses and cash burn despite revenue growth. Technical analysis indicates bearish momentum, while mixed corporate events highlight both opportunities and setbacks in their pipeline. The valuation is unattractive due to negative earnings, further impacting the score.
To see Spark’s full report on PRTA stock, click here.
More about Prothena
Average Trading Volume: 1,466,443
Technical Sentiment Signal: Sell
Current Market Cap: $304.7M
See more insights into PRTA stock on TipRanks’ Stock Analysis page.